Welcome to our dedicated page for Sanara Medtech SEC filings (Ticker: SMTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating critical details on collagen efficacy studies, FDA clearances, and insider share movements across Sanara MedTech’s dense SEC filings can feel like performing surgery without proper lighting. The company’s focus on advanced wound care means its 10-K annual report is packed with clinical trial data, R&D expenses, and licensing disclosures that easily surpass 200 pages.
Stock Titan’s AI-powered platform removes that complexity. Our system parses every Sanara MedTech quarterly earnings report 10-Q filing, highlights shifts in gross margin from surgical wound products, and delivers plain-English explanations of each risk factor. Form 4 alerts surface Sanara MedTech insider trading Form 4 transactions the moment they hit EDGAR, so you can spot executive stock activity in real time. Need to decode an 8-K about a newly cleared collagen dressing? The "Sanara MedTech 8-K material events explained" module summarizes the impact on revenue guidance within seconds.
Whether you’re comparing segment performance, checking Sanara MedTech proxy statement executive compensation, or simply searching for "Sanara MedTech SEC filings explained simply," our coverage spans every document type: 10-K, 10-Q, 8-K, DEF 14A, S-1, and more. AI-generated keyword tagging lets you jump straight to reimbursement discussions, while expert commentary outlines how collagen science drives top-line growth. Stop wading through PDFs—access Sanara MedTech annual report 10-K simplified, monitor Sanara MedTech Form 4 insider transactions real-time, and understand each filing’s relevance to wound-care innovation in one streamlined hub.
Sanara MedTech Inc. (SMTI)$26,333,819 from $21,671,599 a year ago, led by soft tissue repair products ($23,424,126) and bone fusion products ($2,909,693). Gross profit increased to $24,459,605, and operating income from continuing operations improved to $2,941,240 versus $778,537 last year. Continuing operations posted net income of $834,493 in Q3 and $714,186 year‑to‑date.
The company discontinued its THP segment in mid‑September and recorded an asset impairment charge of $26,472,407, driving Q3 net loss to $(30,412,108) and year‑to‑date net loss to $(35,957,889). Cash was $14,939,646 with positive operating cash flow of $2,841,568 for the nine months. Long‑term debt increased to $45,089,787, contributing to higher interest expense ($1,818,105 in Q3). Shareholders’ equity declined to $6,140,534. As of November 11, 2025, 8,935,657 common shares were outstanding.
Sanara MedTech Inc. (SMTI) reported that it issued a press release with financial results for the quarter ended September 30, 2025. The company furnished this information on a Form 8-K dated November 12, 2025, with the press release included as Exhibit 99.1.
The submission states that the press release and related information are furnished and not deemed “filed” under Section 18 of the Exchange Act, which limits associated liabilities. SMTI’s common stock trades on the Nasdaq Capital Market under the symbol SMTI.
Sanara MedTech Inc. (SMTI) disclosed a business update, announcing a strategic realignment that includes discontinuing operations of its Tissue Health Plus. The company communicated this decision via a press release issued on November 11, 2025, which is furnished as Exhibit 99.1.
The press release is provided for information purposes and is not deemed filed under Section 18 of the Exchange Act or incorporated by reference into other filings unless expressly stated.
Sanara MedTech Inc. (SMTI) reported a grant of restricted common stock to CEO Seth D. Yon. The Form 4 shows the reporting person was granted 28,563 restricted shares on 09/15/2025 at no cash price, increasing his beneficial ownership to 89,851 shares. The restricted stock award was made under the company's 2024 Omnibus Long-Term Incentive Plan and vests in three equal installments on 09/15/2026, 09/15/2027 and 09/15/2028, contingent on continued employment through each vesting date. The filing is a routine Section 16 disclosure documenting the grant and resulting ownership position.
Sanara MedTech Inc. (SMTI) Form 3 shows Ashley M. Mackey reported beneficial ownership of 2,412 shares of the issuer's common stock. The report cites an event date of 08/29/2025 and the form is signed on 09/04/2025. The filing identifies the reporting person as a Director and indicates Controller in the relationship field. No derivative securities or additional holdings are reported.
Sanara MedTech Inc. director and Chief Accounting & Chief Administrative Officer Michael D. McNeil reported a Form 4 showing an 08/19/2025 transaction in which 2,324 shares of common stock were withheld to satisfy tax withholding for the accelerated vesting of 9,543 restricted shares previously granted. The filing states no shares were issued or sold; the per-share withholding value was $30.86, reflecting the Nasdaq market price on the vesting date. After the withholding, Mr. McNeil beneficially owns 28,587 common shares.
Sanara MedTech Inc. reported quarterly net revenue of $25.83 million and six‑month net revenue of $49.26 million, increases versus the prior year driven by higher sales of soft tissue repair and bone fusion products. Gross profit rose to $23.89 million for the quarter, reflecting strong product margins despite modest cost of goods sold.
The company recorded a net loss attributable to shareholders of $2.01 million for the quarter (net loss per share $0.23), improved from a loss of $3.50 million the prior year quarter; year‑to‑date net loss was $5.54 million (vs. $5.27 million prior year). Cash increased to $16.96 million and total assets grew to $98.77 million. Leverage rose materially: long‑term debt, net of issuance costs, was $44.22 million (up from $30.69 million) following additional borrowings under the CRG Term Loan. The company completed the CarePICS acquisition on April 1, 2025 (total purchase consideration $3.48 million) and recorded higher investments and earnout liabilities. The period shows revenue growth and improved quarterly profitability but higher interest and contingent obligations from financing and acquisitions.
Sanara MedTech Inc. announced its financial results for the quarter ended June 30, 2025 via a press release furnished as Exhibit 99.1 to this Current Report. The report explicitly states the press release is furnished rather than filed, and therefore the exhibit is not subject to Section 18 liability nor automatically incorporated by reference into other securities filings unless expressly stated.
The body of the Current Report contains no financial figures or performance metrics, so readers must consult Exhibit 99.1 for the company’s detailed results and any quantitative disclosures.
Sanara MedTech (ticker SMTI) is listed on the Nasdaq Capital Market and identifies its principal executive offices in Fort Worth, Texas.
FAQ
What is the current stock price of Sanara Medtech (SMTI)?
What is the market cap of Sanara Medtech (SMTI)?
